Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on May 1, 2026 to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on May 1, 2026 to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). The grants total 135,000 non-qualified stock options with a 10-year term and an exercise price of $87.42 per share.

Options vest 25% after one year then monthly over 36 months and are governed by the company's Equity Inducement Plan and individual stock option agreements.

Argus May 4 session

+2.20% close to close Open Argus

Details

News Market Reaction – DNTH

On May 4, the first trading day after this news, DNTH closed 2.20% above the previous close.

Data tracked by StockTitan Argus for the May 4 session.

Key Figures

New hires: 6 employees Option grants: 135,000 shares Option term: 10 years +3 more

New hires

6 employees

Number of newly hired non-executive employees receiving inducement grants on May 1, 2026

Option grants

135,000 shares

Aggregate non-qualified stock options granted as inducement awards

Option term

10 years

Term of the non-qualified stock options under the inducement grants

Exercise price

$87.42 per share

Exercise price for the inducement non-qualified stock options

Initial vesting

25%

Portion of options vesting on first anniversary of vesting commencement date

Remaining vesting period

36 months

Period over which remaining options vest in equal monthly installments

Historical Context

5 past events · Latest: Apr 06

5 events

1. Apr 06

   Inducement grants

   24h Move

   +0.8%

   Equity inducement options granted to new non-executive employees.

2. Mar 12

   Offering closing

   24h Move

   -3.1%

   Closed upsized underwritten offering raising about $719M in gross proceeds.

3. Mar 10

   Offering pricing

   24h Move

   -1.2%

   Priced upsized $625M underwritten offering of shares and pre-funded warrants.

4. Mar 09

   Offering proposed

   24h Move

   +9.7%

   Proposed $400M underwritten public offering with $60M overallotment option.

5. Mar 09

   Earnings & trial

   24h Move

   +21.5%

   Phase 3 GO decision and Q4/FY 2025 results with cash of $514.4M and long runway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, equity inducement plan

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"The inducement grants were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"The inducement grants consist of non-qualified stock options to purchase an aggregate of 135,000 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

equity inducement plan financial

"The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan..."

An equity inducement plan is a program that gives new hires or targeted employees stock, restricted shares, or stock options as a hiring or retention reward, often separate from the company’s regular long-term incentive plans. Think of it as a signing bonus paid in company stock: it helps attract and keep talent but matters to investors because it can dilute existing shares, change executive incentives, and affect future earnings through compensation expense.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on May 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 135,000 shares of the Company's common stock with a 10-year term and an exercise price of $87.42 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dianthus Therapeutics (DNTH) announce about inducement grants on May 1, 2026?

They granted 135,000 non-qualified stock options to six new non-executive hires on May 1, 2026. According to Dianthus, the options have a 10-year term, an exercise price of $87.42, and vest under the company inducement plan.

How do the DNTH inducement option vesting terms work for the new hires?

Options vest 25% on the first anniversary of the vesting start date, then monthly over 36 months. According to Dianthus, the remaining 75% vests in equal monthly installments across the subsequent three years.

What is the exercise price and term for the Dianthus (DNTH) inducement stock options?

The exercise price is $87.42 per share and the options carry a 10-year term. According to Dianthus, these are non-qualified stock options subject to the Equity Inducement Plan and option agreements.

Who approved the DNTH inducement grants and under which Nasdaq rule were they made?

The company's independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4). According to Dianthus, the awards were made as material inducements to accept employment with the company.

How many employees received inducement grants from Dianthus (DNTH) and how many shares are covered?

Six newly hired, non-executive employees received inducement awards covering an aggregate of 135,000 option shares. According to Dianthus, the awards were granted on May 1, 2026 under the inducement plan.